- Home
- INMB vs VRCA Comparison
INMB vs VRCA Comparison
Compare INMB & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- VRCA
- Stock Information
- Founded
- INMB 2015
- VRCA 2013
- Country
- INMB United States
- VRCA United States
- Employees
- INMB N/A
- VRCA N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- INMB Health Care
- VRCA Health Care
- Exchange
- INMB Nasdaq
- VRCA Nasdaq
- Market Cap
- INMB 49.2M
- VRCA 40.6M
- IPO Year
- INMB 2019
- VRCA 2018
- Fundamental
- Price
- INMB $1.87
- VRCA $3.64
- Analyst Decision
- INMB Hold
- VRCA Hold
- Analyst Count
- INMB 3
- VRCA 3
- Target Price
- INMB $4.30
- VRCA $20.00
- AVG Volume (30 Days)
- INMB 349.2K
- VRCA 374.8K
- Earning Date
- INMB 10-30-2025
- VRCA 11-06-2025
- Dividend Yield
- INMB N/A
- VRCA N/A
- EPS Growth
- INMB N/A
- VRCA N/A
- EPS
- INMB N/A
- VRCA N/A
- Revenue
- INMB $50,000.00
- VRCA $14,704,000.00
- Revenue This Year
- INMB $264.29
- VRCA $332.45
- Revenue Next Year
- INMB $9,819.61
- VRCA $12.85
- P/E Ratio
- INMB N/A
- VRCA N/A
- Revenue Growth
- INMB N/A
- VRCA 5.72
- 52 Week Low
- INMB $1.71
- VRCA $3.60
- 52 Week High
- INMB $11.64
- VRCA $17.38
- Technical
- Relative Strength Index (RSI)
- INMB 45.15
- VRCA 34.17
- Support Level
- INMB $1.79
- VRCA $3.60
- Resistance Level
- INMB $1.95
- VRCA $3.96
- Average True Range (ATR)
- INMB 0.10
- VRCA 0.26
- MACD
- INMB 0.01
- VRCA -0.04
- Stochastic Oscillator
- INMB 46.00
- VRCA 4.26
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.